Related Experiment Video

Updated: Apr 16, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

8.9K

RNA interference targeting enhancer of polycomb1 exerts anti-tumor effects in lung cancer

Chunli Che1, Lijuan Zhang1, Jianmin Huo1

  • 1Department of Respiratory Medicine, First Clinical Medical College Affiliated to Harbin Medical University Harbin 150001, China.

International Journal of Clinical and Experimental Pathology
|March 11, 2015
PubMed
Abstract

Insights

Silencing enhancer of polycomb1 (EPC1) using short hairpin RNA (shRNA) inhibits lung cancer cell proliferation and tumor growth. This study identifies EPC1 as a potential new therapeutic target for lung cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Lung cancer is a leading cause of cancer mortality worldwide.
  • Identifying novel therapeutic targets is crucial for improving lung cancer treatment outcomes.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting enhancer of polycomb1 (EPC1) in lung cancer.
  • To evaluate the effects of EPC1 down-regulation using short hairpin RNA (shRNA) on lung cancer cells and tumor growth.

Main Methods:

  • Utilized RNA interference with specific shRNA delivered via lentivirus to down-regulate EPC1 expression in A549 lung cancer cells.
  • Assessed cell survival and apoptosis using MTT assays and flow cytometry.
  • Evaluated tumor growth inhibition in a mouse xenograft model.
  • Measured protein levels of AKT and p65 via western blotting.

Main Results:

  • Down-regulation of EPC1 significantly reduced A549 cell survival and increased apoptosis.
  • Tumor size and weight were significantly reduced in the EPC1 shRNA group compared to controls.
  • EPC1 shRNA led to decreased expression of phosphorylated AKT (p-AKT) and p65 in both in vitro and in vivo models.

Conclusions:

  • Silencing EPC1 through shRNA demonstrates potent inhibition of lung cancer cell proliferation and tumor growth.
  • EPC1 represents a promising novel therapeutic target for lung cancer treatment.
Keywords:
EPC1Lung cancershRNA

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K